Generic Name: romidepsin

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Chemotherapy Medications

Company: Celgene

Approval Status: Approved

Generic Version Available: No

Experimental Code: N/A


Drug Indication

Istodax is an HDAC inhibitor approved for previously treated cutaneous and peripheral T-cell lymphoma.


General Info

Istodax is a histone deacetylase (HDAC) inhibitor that disables an enzyme that keeps DNA tightly coiled. It works by activating genes that halt cancer cell growth.


Dosage

Dosing Info:

Istodax is administered by intravenous infusion. It is usually given on three days of a 28-day cycle as long as a patient continues to benefit.


Side Effects

Common side effects include nausea, fatigue, vomiting and loss of appetite. Istodax can cause depletion of red blood cells (anemia), white blood cells (neutropenia) and platelets (thrombocytopenia), which can lead to infections and easy bleeding. Potential severe side effects include heart rhythm abnormalities and tumor lysis syndrome, a reaction that can occur when cancer cells die suddenly. Istodax may cause fetal harm if used during pregnancy.


For More Info: https://media.celgene.com/content/uploads/istodax-pi.pdf

Last Reviewed: November 29, 2018